TVGN: Tevogen Bio Holdings Inc. Common Stock Stocks News on July 27, 2024

Tevogen Bio Issues Letter to Stockholders Highlighting Recent Achievements, Growth Plans, and Consideration of a Potential Share Buyback

TVGN

GlobeNewswire

15 days ago

Tevogen Bio Issues Letter to Stockholders Highlighting Recent Achievements, Growth Plans, and Consideration of a Potential Share Buyback

Tevogen Bio’s R&D Leadership Discusses The Promise of Its Genetically Unmodified, Off-The-Shelf T Cell Technology For The Treatment of Infectious Diseases, Cancers, and Neurological Disorders With Nasdaq's Kristina Ayanian

TVGN

GlobeNewswire

17 days ago

Tevogen Bio’s R&D Leadership Discusses The Promise of Its Genetically Unmodified, Off-The-Shelf T Cell Technology For The Treatment of Infectious Diseases, Cancers, and Neurological Disorders With Nasdaq's Kristina Ayanian

Ryan Saadi Congratulates Marc Benioff on Receiving the Yale Legend in Leadership Award and Commends Yale School of Management for Recognizing the Importance of Integrating Corporate Success with Social Responsibility

TVGN

GlobeNewswire

18 days ago

Ryan Saadi Congratulates Marc Benioff on Receiving the Yale Legend in Leadership Award and Commends Yale School of Management for Recognizing the Importance of Integrating Corporate Success with Social Responsibility

Tevogen Bio Files Registration Statement for Previously Disclosed Securities; Does Not Relate to Any Previously Undisclosed New Issuances of Dilutive Securities

TVGN

GlobeNewswire

a month ago

Tevogen Bio Files Registration Statement for Previously Disclosed Securities; Does Not Relate to Any Previously Undisclosed New Issuances of Dilutive Securities

TVGN

GlobeNewswire

a month ago

Tevogen Bio Announces Publication of Positive Phase I Clinical Trial Results for TVGN 489 in Blood Advances

Tevogen.AI Head Discusses Company’s Bold Strategy to Shape the Future of T Cell Therapies at Longwood Spring MIT Conference

TVGN

GlobeNewswire

a month ago

Tevogen.AI Head Discusses Company’s Bold Strategy to Shape the Future of T Cell Therapies at Longwood Spring MIT Conference

Tevogen Bio Set to Join Russell 3000® Index

TVGN

GlobeNewswire

a month ago

Tevogen Bio Set to Join Russell 3000® Index

Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts

TVGN

GlobeNewswire

a month ago

Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts

NexTech Solutions Has Agreed to Acquire Rome Research Corporation to Expand Service Offerings and Enhance Mission Support Capabilities

TVGN

PR Newswire

2 months ago

NexTech Solutions Has Agreed to Acquire Rome Research Corporation to Expand Service Offerings and Enhance Mission Support Capabilities

Enhancing the Power of PTZs: Canon Announces New PTZ Firmware Updates Lending Greater Control and Operability, Including an Auto-Tracking Lite Version on Compatible PTZ Models*

TVGN

GlobeNewswire

2 months ago

Enhancing the Power of PTZs: Canon Announces New PTZ Firmware Updates Lending Greater Control and Operability, Including an Auto-Tracking Lite Version on Compatible PTZ Models*

TVGN

Business Wire

2 months ago

Form 8.3 - International Distribution Services plc

TVGN

Business Wire

2 months ago

Form 8.3 - Darktrace plc

US Supreme Court rejects Kroger challenge to Grubhub trademark win

TVGN

Reuters

2 months ago

US Supreme Court rejects Kroger challenge to Grubhub trademark win

Dow Jones Falls As AMD Slides On Downgrade; Nvidia Stock Split Takes Effect

TVGN

Investor's Business Daily

2 months ago

Dow Jones Falls As AMD Slides On Downgrade; Nvidia Stock Split Takes Effect

GoldATM Supports Growing Consumer Demand for Gold Purchase with New ATMs in North Carolina

TVGN

Business Wire

2 months ago

GoldATM Supports Growing Consumer Demand for Gold Purchase with New ATMs in North Carolina

TVGN

GlobeNewswire

2 months ago

Middlefield Canadian Income PCC: Net Asset Value(s)

CORRECTION – Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Public Listing Social Engagement Event

TVGN

GlobeNewswire

2 months ago

CORRECTION – Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Public Listing Social Engagement Event

Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Listing Social Engagement Event

TVGN

GlobeNewswire

2 months ago

Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Listing Social Engagement Event

TVGN

GlobeNewswire

2 months ago

Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2

Tevogen Bio Reports First Quarter 2024 Financial Results

TVGN

GlobeNewswire

2 months ago

Tevogen Bio Reports First Quarter 2024 Financial Results

Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives

TVGN

GlobeNewswire

2 months ago

Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives

Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives

TVGN

GlobeNewswire

3 months ago

Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives

Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives

TVGN

GlobeNewswire

3 months ago

Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives

Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments

TVGN

GlobeNewswire

3 months ago

Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments

Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers

TVGN

GlobeNewswire

4 months ago

Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers

Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development

TVGN

GlobeNewswire

4 months ago

Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development

Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price

TVGN

GlobeNewswire

4 months ago

Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price

TVGN

Business Wire

4 months ago

Tevogen Bio Reports Its Investigational SARS-CoV-2 Specific T Cell Therapy, TVGN-489, Retains Activity Against the Dominant JN.1 Variant

Tevogen Bio Holdings Congratulates its Board Member and Esteemed Global Safety Management Expert, Victor Sordillo, on His appointment as Managing Director of Risk Advisory Services at Verita

TVGN

Business Wire

5 months ago

Tevogen Bio Holdings Congratulates its Board Member and Esteemed Global Safety Management Expert, Victor Sordillo, on His appointment as Managing Director of Risk Advisory Services at Verita

TVGN

Simply Wall St.

5 months ago

With a 86% stake, Tevogen Bio Holdings Inc. (NASDAQ:TVGN) insiders have a lot riding on the company

Mittul Mehta, Head of Tevogen's Artificial Intelligence Initiative Tevogen.ai, Emphasizes Importance of Proactive Talent Development for Biopharmaceutical Sector to Allow Rapid Adoption of AI

TVGN

Business Wire

5 months ago

Mittul Mehta, Head of Tevogen's Artificial Intelligence Initiative Tevogen.ai, Emphasizes Importance of Proactive Talent Development for Biopharmaceutical Sector to Allow Rapid Adoption of AI

Cell Therapy Company Tevogen Bio Holdings Inc. Prepares to Launch Crucial Genetic Predisposition Study in Preparation to Investigate the Potential of TVGN 489 to Address Critical Unmet Need for Long COVID Treatment

TVGN

Business Wire

5 months ago

Cell Therapy Company Tevogen Bio Holdings Inc. Prepares to Launch Crucial Genetic Predisposition Study in Preparation to Investigate the Potential of TVGN 489 to Address Critical Unmet Need for Long COVID Treatment

TVGN

Business Wire

5 months ago

Cell Therapy Company Tevogen Bio Holdings Inc. (Nasdaq: TVGN) Rings Opening Bell at Nasdaq Exchange on February 15th, 2024, Begins Public Trading on the Open Market

Tevogen Bio Announces $8 Million Equity Investment

TVGN

Business Wire

5 months ago

Latest Tevogen Bio Holdings Inc. Common Stock (TVGN) News on July 27, 2024

Tevogen Bio Issues Letter to Stockholders Highlighting Recent Achievements, Growth Plans, and Consideration of a Potential Share Buyback

Tevogen Bio’s R&D Leadership Discusses The Promise of Its Genetically Unmodified, Off-The-Shelf T Cell Technology For The Treatment of Infectious Diseases, Cancers, and Neurological Disorders With Nasdaq's Kristina Ayanian

Ryan Saadi Congratulates Marc Benioff on Receiving the Yale Legend in Leadership Award and Commends Yale School of Management for Recognizing the Importance of Integrating Corporate Success with Social Responsibility

Tevogen Bio Files Registration Statement for Previously Disclosed Securities; Does Not Relate to Any Previously Undisclosed New Issuances of Dilutive Securities

Tevogen Bio Announces Publication of Positive Phase I Clinical Trial Results for TVGN 489 in Blood Advances

Tevogen.AI Head Discusses Company’s Bold Strategy to Shape the Future of T Cell Therapies at Longwood Spring MIT Conference

Tevogen Bio Set to Join Russell 3000® Index

Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts

NexTech Solutions Has Agreed to Acquire Rome Research Corporation to Expand Service Offerings and Enhance Mission Support Capabilities

Enhancing the Power of PTZs: Canon Announces New PTZ Firmware Updates Lending Greater Control and Operability, Including an Auto-Tracking Lite Version on Compatible PTZ Models*

Form 8.3 - International Distribution Services plc

Form 8.3 - Darktrace plc

US Supreme Court rejects Kroger challenge to Grubhub trademark win

Dow Jones Falls As AMD Slides On Downgrade; Nvidia Stock Split Takes Effect

GoldATM Supports Growing Consumer Demand for Gold Purchase with New ATMs in North Carolina

Middlefield Canadian Income PCC: Net Asset Value(s)

CORRECTION – Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Public Listing Social Engagement Event

Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Listing Social Engagement Event

Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2

Tevogen Bio Reports First Quarter 2024 Financial Results

Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives

Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives

Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives

Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments

Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers

Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development

Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price

Tevogen Bio Reports Its Investigational SARS-CoV-2 Specific T Cell Therapy, TVGN-489, Retains Activity Against the Dominant JN.1 Variant

Tevogen Bio Holdings Congratulates its Board Member and Esteemed Global Safety Management Expert, Victor Sordillo, on His appointment as Managing Director of Risk Advisory Services at Verita

With a 86% stake, Tevogen Bio Holdings Inc. (NASDAQ:TVGN) insiders have a lot riding on the company

Mittul Mehta, Head of Tevogen's Artificial Intelligence Initiative Tevogen.ai, Emphasizes Importance of Proactive Talent Development for Biopharmaceutical Sector to Allow Rapid Adoption of AI

Cell Therapy Company Tevogen Bio Holdings Inc. Prepares to Launch Crucial Genetic Predisposition Study in Preparation to Investigate the Potential of TVGN 489 to Address Critical Unmet Need for Long COVID Treatment

Cell Therapy Company Tevogen Bio Holdings Inc. (Nasdaq: TVGN) Rings Opening Bell at Nasdaq Exchange on February 15th, 2024, Begins Public Trading on the Open Market

Tevogen Bio Announces $8 Million Equity Investment

Share on Social Networks: